MALT Lymphoma Clinical Trial
Official title:
Eradication of Helicobacter Pylori in the Management of Stage IE & IIE-1 Primary Low-grade B Cell Lymphoma of Mucosa-associated Lymphoid Tissue Type of The Stomach
To evaluate the therapeutic effectiveness of H. pylori eradication in stage IE & IIE-1 primary low-grade B cell lymphoma of MALT of the stomach
To investigate the prevalence of H. pylori infection in patients with early stage of primary
low-grade B cell lymphoma of MALT of the stomach in Taiwan.
-To evaluate the therapeutic effectiveness of H. pylori eradication in stage IE & IIE-1
primary low-grade B cell lymphoma of MALT of the stomach.
To evaluate the efficacy of Helicobacter pylori eradication therapy with respect to
objective regression rate and time to disease progression of primary low-grade gastric
MALToma.
To estimate any differences in therapeutic efficacy related to different stage of
disease,eg. stage IE v.s. stage IIE-1.
To identify the causes of treatment failure, such as the stage of tumor, the presence of
large cell component, and/or persistent, reactivation or reinfection of H. pylori etc.
;
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05003141 -
PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies
|
Phase 1 | |
| Completed |
NCT01015248 -
Trial of Bendamustine And Rituximab for Patients With Previously Untreated Extranodal Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma
|
Phase 2 | |
| Completed |
NCT00373646 -
Thalidomide in Mucosa Associated Lymphoid Tissue (MALT) Lymphoma Patients
|
Phase 2 | |
| Unknown status |
NCT00923663 -
Trial of Lenalidomide in Patients With Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) Type
|
Phase 2 | |
| Completed |
NCT00783367 -
Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas
|
Phase 2 | |
| Active, not recruiting |
NCT01808599 -
Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma
|
Phase 2 | |
| Completed |
NCT00117156 -
Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymphoma
|
Phase 2 | |
| Recruiting |
NCT05544019 -
Study of SGR-1505 in Mature B-Cell Neoplasms
|
Phase 1 | |
| Completed |
NCT00373906 -
Velcade in MALT Lymphoma Patients
|
Phase 2 |